Literature DB >> 35576171

PD-1 Inhibition-Trouble for Subsequent TIL Therapy in Patients with Melanoma?

Eryn Blass1,2, Patrick A Ott1,2,3,4,5.   

Abstract

To explore the lower efficacy of adoptive cell transfer (ACT) therapy in patients with anti-PD-1 experienced melanoma, tumor mutational burden (TMB), predicted neoantigen frequencies, and tumor-infiltrating lymphocyte (TIL) neoantigen reactivity were assessed. Reduced neoantigen-specific TIL frequencies correlated with lower ACT response even in patients with similar TMB, suggesting a potentially harmful effect of PD-1 inhibition on T-cell outgrowth. See related article by Levi et al., p. 3042. ©2022 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2022        PMID： 35576171      PMCID： PMC9288489          DOI： 10.1158/1078-0432.CCR-22-0832

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  5 in total

1.  PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.

Authors:  Vivek Verma; Rajeev K Shrimali; Shamim Ahmad; Winjie Dai; Hua Wang; Sumin Lu; Rahul Nandre; Pankaj Gaur; Jose Lopez; Moshe Sade-Feldman; Keren Yizhak; Stacey L Bjorgaard; Keith T Flaherty; Jennifer A Wargo; Genevieve M Boland; Ryan J Sullivan; Gad Getz; Scott A Hammond; Ming Tan; Jingjing Qi; Phillip Wong; Taha Merghoub; Jedd Wolchok; Nir Hacohen; John E Janik; Mikayel Mkrtichyan; Seema Gupta; Samir N Khleif
Journal:  Nat Immunol       Date:  2019-07-29       Impact factor: 25.606

2.  Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.

Authors:  Imran Siddiqui; Karin Schaeuble; Vijaykumar Chennupati; Silvia A Fuertes Marraco; Sandra Calderon-Copete; Daniela Pais Ferreira; Santiago J Carmona; Leonardo Scarpellino; David Gfeller; Sylvain Pradervand; Sanjiv A Luther; Daniel E Speiser; Werner Held
Journal:  Immunity       Date:  2019-01-08       Impact factor: 31.745

3.  Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-PD-1 Naïve and Experienced Patients with Metastatic Melanoma.

Authors:  Shoshana T Levi; Amy R Copeland; Shirley Nah; Jessica S Crystal; Gabriel D Ivey; Almin Lalani; Mohammad Jafferji; Bradley S White; Neilesh B Parikh; Vid Leko; Sri Krishna; Frank Lowery; Todd D Prickett; Jared J Gartner; Li Jia; Yong F Li; Abraham Sachs; Sivasish Sindiri; Welles Robinson; Billel Gasmi; James C Yang; Stephanie L Goff; Steven A Rosenberg; Paul F Robbins
Journal:  Clin Cancer Res       Date:  2022-07-15       Impact factor: 13.801

4.  The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection.

Authors:  Kristen E Pauken; Jernej Godec; Pamela M Odorizzi; Keturah E Brown; Kathleen B Yates; Shin Foong Ngiow; Kelly P Burke; Seth Maleri; Shannon M Grande; Loise M Francisco; Mohammed-Alkhatim Ali; Sabrina Imam; Gordon J Freeman; W Nicholas Haining; E John Wherry; Arlene H Sharpe
Journal:  Cell Rep       Date:  2020-06-30       Impact factor: 9.423

5.  Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.

Authors:  Sri Krishna; Frank J Lowery; Amy R Copeland; Erol Bahadiroglu; Ratnadeep Mukherjee; Li Jia; James T Anibal; Abraham Sachs; Serifat O Adebola; Devikala Gurusamy; Zhiya Yu; Victoria Hill; Jared J Gartner; Yong F Li; Maria Parkhurst; Biman Paria; Pia Kvistborg; Michael C Kelly; Stephanie L Goff; Grégoire Altan-Bonnet; Paul F Robbins; Steven A Rosenberg
Journal:  Science       Date:  2020-12-11       Impact factor: 47.728
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.